Tim Jasper Knotnerus - 18 Mar 2026 Form 3 Insider Report for Agomab Therapeutics NV (AGMB)

Role: Chief Executive Officer, Director
Signature: /s/ Ellen Lefever, Attorney-in-Fact
Issuer symbol: AGMB
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 16:01:46 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Knotnerus Tim Jasper	Chief Executive Officer, Director	AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM	/s/ Ellen Lefever, Attorney-in-Fact	18 Mar 2026	0002120886

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AGMB	Common shares						10,823	18 Mar 2026	Direct	F1
holding	AGMB	Common shares						34,394	18 Mar 2026	By TJK Life Sciences B.V.	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	58,918	$1.13	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	43,853	$1.13	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	37,144	$1.13	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	83,507	$1.13	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	308,875	$0.000500	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	104,394	$0.000500	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	307,793	$0.000500	Direct	F1, F3, F4
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	18,875	$0.000500	Direct	F1, F4, F5
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	683,248	$0.000500	Direct	F1, F4, F5
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	436,268	$14.26	Direct	F1, F4, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F2	Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3	The shares underlying this option are fully vested and exercisable.
F4	The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
F5	50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F6	25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney